Sakamoto, Taiji http://orcid.org/0000-0003-0287-3801
Shimura, Masahiko
Kitano, Shigehiko
Ohji, Masahito
Ogura, Yuichiro
Yamashita, Hidetoshi
Suzaki, Makoto
Mori, Kimie
Ohashi, Yohei
Yap, Poh Sin
Kaneko, Takeumi
Ishibashi, Tatsuro
,
Funding for this research was provided by:
Novartis Pharma K.K.
Article History
Received: 5 March 2021
Revised: 17 June 2021
Accepted: 29 June 2021
First Online: 3 September 2021
Declarations
:
: The study protocol and informed consent form were reviewed and approved by each centre’s institutional review board. This study was conducted in accordance with the principles of the Declaration of Helsinki and the guidelines for Good Clinical Practice, Good Post-marketing Study Practice and Good Pharmacoepidemiology Practices.
: All patients or their legal representatives provided written informed consent.
: Not applicable.
: Taiji Sakamoto reports personal fees from Novartis Pharma K.K. (Tokyo, Japan) for this study; has worked as a consultant for Bayer (Osaka, Japan) and received personal fees; has received grant support from Chugai (Tokyo, Japan), Senju (Osaka, Japan), Novartis Pharma K.K. (Tokyo, Japan) and Parexel (Tokyo, Japan); and has received personal fees (lecture fees) from Santen (Osaka, Japan), Bayer (Osaka, Japan), Novartis Pharma K.K. (Tokyo, Japan), Alcon (Tokyo, Japan), Otsuka (Tokyo, Japan), Senju (Osaka, Japan), Kowa (Aichi, Japan), Wakamoto (Tokyo, Japan), MSD (Tokyo, Japan), Bausch & Lomb (Tokyo, Japan), Chuo Sangiyo (Hyogo, Japan), Japan Ophthalmic Instruments Association (Tokyo, Japan), Parexel (Tokyo, Japan), Nidek (Aichi, Japan), R E Medical (Osaka, Japan), KY CenterVue (Tokyo, Japan) and Chugai (Tokyo, Japan) outside the submitted work. Masahiko Shimura has received grant support from Novartis Pharma K.K. (Tokyo, Japan) and Bayer (Osaka, Japan) outside the submitted work. Shigehiko Kitano has received personal fees from Novartis Pharma K.K. (Tokyo, Japan) for this study; grant support from Novartis Pharma K.K. (Tokyo, Japan), Bayer (Osaka, Japan), Senju (Osaka, Japan), Santen (Osaka, Japan), Alcon (Tokyo, Japan) and Otsuka (Tokyo, Japan); and personal fees (lecture fees) from Novartis Pharma K.K. (Tokyo, Japan), Kowa (Aichi, Japan), MSD (Tokyo, Japan), Bayer (Osaka, Japan) and Novo Nordisk (Tokyo, Japan) outside the submitted work. Masahito Ohji has received personal fees from Novartis Pharma K.K. (Tokyo, Japan) for this study; personal fees for work as a consultant for Allergan (Tokyo, Japan), Bayer (Osaka, Japan), HOYA (Tokyo, Japan), Novartis Pharma K.K. (Tokyo, Japan), Chengdu Kanghong Biotechnology (Chengdu, China) and Alcon (Tokyo, Japan); grant support from Santen (Osaka, Japan), Novartis Pharma K.K. (Tokyo, Japan), Alcon (Tokyo, Japan), Otsuka (Tokyo, Japan), Senju (Osaka, Japan), Pfizer (Tokyo, Japan), HOYA (Tokyo, Japan) and AMO (Tokyo, Japan); and personal fees (lecture fees) from Santen (Osaka, Japan), Novartis Pharma K.K. (Tokyo, Japan), Bayer (Tokyo, Japan), Alcon (Tokyo, Japan), Otsuka (Tokyo, Japan), Kowa (Aichi, Japan) and Senju (Osaka, Japan) outside the submitted work. Yuichiro Ogura has received personal fees from Novartis Pharma K.K. (Tokyo, Japan) for this study; personal fees for work as a consultant for Bayer (Osaka, Japan), Novartis Pharma K.K. (Tokyo, Japan), HOYA (Tokyo, Japan), Kowa (Aichi, Japan), Astellas (Tokyo, Japan), Janssen (Tokyo, Japan), Alcon (Tokyo, Japan), Graybug (CA, USA), Kyoto Drug Discovery & Development (Kyoto, Japan), Allergan (Tokyo, Japan) and Chugai (Tokyo, Japan); grant support from Boehringer Ingelheim (Tokyo, Japan) and Novartis Pharma K.K. (Tokyo, Japan); and personal fees (lecture fees) from Bayer (Osaka, Japan), Novartis Pharma K.K. (Tokyo, Japan), Santen (Osaka, Japan), Senju (Osaka, Japan), Sanwa Kagaku (Aichi, Japan), Wakamoto (Tokyo, Japan), Otsuka (Tokyo, Japan), Topcon (Tokyo, Japan) and Nikon (Tokyo, Japan) outside the submitted work. Hidetoshi Yamashita has received personal fees from Novartis Pharma K.K. (Tokyo, Japan) for this study; grant support from Novartis Pharma K.K. (Tokyo, Japan), Alcon (Tokyo, Japan), Santen (Osaka, Japan), Senju (Osaka, Japan), AMO (Tokyo, Japan), Trust Medical (Miyagi, Japan) and Atsuzawa Prosthesis (Tokyo, Japan); and personal fees (lecture fees) from Novartis Pharma K.K. (Tokyo, Japan), Santen (Osaka, Japan), Senju (Osaka, Japan), Bausch & Lomb (Tokyo, Japan) and Bayer (Osaka, Japan) outside the submitted work. Makoto Suzaki, Kimie Mori, Yohei Ohashi and Takeumi Kaneko are employees of Novartis Pharma K.K. (Tokyo, Japan). Poh Sin Yap is an employee of Novartis Corporation Sdn. Bhd. (Selangor, Malaysia). Tatsuro Ishibashi has received personal fees from Novartis Pharma K.K. (Tokyo, Japan) for this study and lecture fees from Santen (Osaka, Japan), Bayer (Osaka, Japan), Otsuka (Tokyo, Japan), Bausch & Lomb (Tokyo, Japan), Rohto (Osaka, Japan), Senju (Osaka, Japan) and Novartis Pharma K.K. (Tokyo, Japan) outside the submitted work.